Basilea gets closer to profitability with increased revenue driven by Cresemba and Zevtera sales. Aims US market with its oncology program
Basilea Pharmaceutica’s revenue in 2017 increased to CHF 101.5 million fromCHF 66.0 million in 2016, which represents an increase of…